Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 927 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
życiorys zawodowy kandydata_PL (tłumaczenie maszynowe)
Regulatory Filings Classification · 20% confidence The document is a standalone professional biography of Dr. Andrew Galazka, machine-translated into Polish, with no indication of a corporate filing, report structure (financial statements, meeting minutes, call transcripts, etc.), or announcement of an event. It does not match any specialized category such as board appointment notice (MANG), investor presentation (IP), or proxy materials (PSI). It contains no voting results, legal notices, or financial figures. It falls into none of the company filing categories and defaults to a general regulatory announcement/fallback.
2026-06-08 Polish
życiorys zawodowy kandydata
Board/Management Information Classification · 90% confidence The document is a standalone executive biography for Dr. Andrew Galazka, detailing his senior management and board-level experience. It does not contain financial performance data or regulatory attestations, nor does it announce an earnings release or dividend. This type of content aligns with Board/Management Information, as it profiles a senior executive likely in connection with a board appointment or management change.
2026-06-08 English
oświadczenie kandydata
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a candidate’s statement (‘Oświadczenie’) submitted to the General Meeting by a nominee for the Supervisory Board, detailing independence and legal qualifications. Such declarations are distributed to shareholders before voting to inform their proxy decision. This aligns with Proxy Solicitation & Information Statement materials (PSI), not a report publication or actual appointment notice.
2026-06-08 Polish
zgłoszenie kandydatury wraz z projektem uchwały
Board/Management Information Classification · 88% confidence The document is a formal notice from a shareholder (an open pension fund) nominating and then effecting the appointment of Mr. Andrew Galazka to the Supervisory Board at the Ordinary General Meeting, and it includes the adopted resolution appointing him. This constitutes an announcement of a change in the company’s board of directors, matching the Board/Management Information category.
2026-06-08 Polish
Zgłoszenie kandydata na członka Rady Nadzorczej Spółki - Content (PL)
Board/Management Information Classification · 85% confidence The document is a current report (raport bieżący) in which the company announces the receipt of a shareholder’s nomination for a candidate to the Supervisory Board, including attached CV and draft resolution. This is an announcement of a change/nomination to the company’s board. Therefore it falls under Board/Management Information (MANG).
2026-06-08 Polish
Śródroczne skrócone skonsolidowane oraz jednostkowe sprawozdanie finansowe sporządzone za okres 3 miesięcy zakończony 31 marca 2026 roku
Interim / Quarterly Report Classification · 98% confidence The document is titled "Środroczne skrócone skonsolidowane oraz jednostkowe sprawozdanie finansowe" for the three-month period ending March 31, 2026. It contains full interim consolidated and standalone financial statements (statement of profit and loss, balance sheet, cash flow, equity changes) and extensive notes. This matches the definition of an Interim/Quarterly Report rather than an announcement or summary. Hence it is classified as IR. Q1 2026
2026-05-27 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.